Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP for short, is a rare neurologic disorder estimated to affect about 10,000 people in the United States, with similar prevalence in Europe and Japan. The disease generally presents in adults in their forties and is marked by cognitive dysfunction, neuropsychiatric symptoms, and motor impairment. There are currently no approved therapies for the treatment of ALSP, highlighting a significant unmet medical need in this rare condition.
The stock we are bringing to your attention is that of Vigil Neuroscience Inc. (VIGL), a company at the forefront of developing a potential breakthrough therapy for ALSP.
For comments and feedback contact: editorial@rttnews.com
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.